Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04450693
Other study ID # TTAX01-CR005
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 20, 2020
Est. completion date September 2024

Study information

Verified date June 2024
Source Tissue Tech Inc.
Contact Kathleen Ripp
Phone 786-753-2037
Email kripp@biotissue.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone. This second confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.


Description:

This trial is designed as a confirmatory study of the benefits and risks of TTAX01 when used in the treatment of Wagner Grades 3 and 4 DFU. Experience with the use of a cryopreserved umbilical cord (UC) product in treating such wounds, both prior to this IND and under this IND, has indicated that a frequency of application of no shorter than every 4 weeks is associated with better than expected outcomes. Although treatment cannot be blinded, a "standard care only" arm is included to control for the benefits of aggressive baseline debridement combined with aggressive (6 weeks systemic) antibiotics. Current treatment guidelines indicate that aggressive debridement plus 1-2 weeks of antibiotics, or, minor debridement plus 6 weeks of antibiotics, would produce equivalent outcomes, although the evidence is not strong. By utilizing both maximum debridement and maximum antimicrobial therapy, the standard care described in this protocol may result in healing rates somewhat superior to current standard practice. The design of this second confirmatory study is matched to the design of the Phase 2 efficacy study TTCRNE-1501, with the exception of extending the primary endpoint from a landmark analysis at 16 to a "wound survival" analysis through 26 weeks, utilizing a proportional risk analysis rather than a simple test of proportions. This design consideration is based on analysis of previous studies (see Background section), and a desire to fold data from every visit into the primary analysis, rather than generating an excessive number of secondary endpoints.


Recruitment information / eligibility

Status Recruiting
Enrollment 220
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - The subject has signed the informed consent form - The subject is male or female, at least 18 years of age inclusive at the date of Screening - The subject has confirmed diagnosis of Type I or Type II diabetes - The subject's index ulcer is located on the plantar surface, inter digital, heel, lateral or medial surface of the foot - The subject has an index ulcer with visible margins having an area = 12.0 cm2 when measured by the electronic measuring device at Screening - The subject's index ulcer extends beyond the dermis, into subcutaneous tissue with evidence of exposed bone, tendon, muscle and/or joint capsule - The subject presents with history, signs or symptoms leading to a clinical suspicion of osteomyelitis in the opinion of the Investigator supported by positive Probe to Bone (PTB) and any of the following: radiographic (X-ray, Magnetic Resonance Imaging (MRI), or bone scan) or evidence of bone necrosis - The subject has an Ankle-Brachial Index = 0.7 to = 1.3 or TcPO2 = 40 mmHg on the dorsum of the affected foot, or Great Toe Pressure = 50 mmHg - The subject is under the care of a physician for the management of Diabetes Mellitus - The subject is willing to return for all mandatory visits as defined in the protocol - The subject is willing to follow the instructions of the trial Investigator Exclusion Criteria: - The subject's index ulcer is primarily located on the dorsal surface of the foot - The subject's index ulcer can be addressed by primary closure through the completion of the initial or staged surgical procedure - The subject has a contralateral major amputation of the lower extremity - The subject has a glycated hemoglobin A1c (HbA1c) level of > 12% † - The subject has been on oral steroid use of > 7.5 mg daily for greater than seven (7) consecutive days in 30 days before Screening - The subject has been on parenteral corticosteroids, or any cytotoxic agents for seven consecutive days in the period of 30 days before Screening - The subject is currently taking the type 2 diabetes medicine canagliflozin (Invokana™, Invokamet™, Invokamet XR™) - The subject has malignancy or a history of cancer, other than non-melanoma skin cancer, in five years before Screening - The subject is pregnant - The subject is a nursing mother - The subject is a woman of child-bearing potential who is unwilling to avoid pregnancy or use an appropriate form of birth control (adequate birth control methods are defined as: topical, oral, implantable, or injectable contraceptives; spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine contraceptive device; or surgical sterilization of partner). - The subject is unable to sustain off-loading as defined by the protocol - The subject has an allergy to primary or secondary dressing materials used in this trial - The subject has an allergy to glycerol - The subject's index ulcer is over an acute Charcot deformity - The subject has had previous use of NEOX®, CLARIX®, or TTAX01 applied to the index ulcer - Per Investigator's discretion the subject is not appropriate for inclusion in the trial, e.g., undergoing surgical treatments listed in the protocol or the subject currently has sepsis, i.e., life-threatening organ dysfunction caused by a dysregulated host response to infection

Study Design


Intervention

Biological:
TTAX01
TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
Other:
Standard care
Standard care is defined in this protocol to consist of the following: Debridement; Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited; Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate; A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin; Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and, Appropriate use of systemic antibiotics.

Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Boston Medical Center Boston Massachusetts
United States Cutting Edge Research, LLC Circleville Ohio
United States University of Texas Southwestern Medical Center Dallas Texas
United States Midland Florida Clinical Research Center DeLand Florida
United States Delray Physician Care Center Delray Beach Florida
United States NorthBay Healthcare Fairfield California
United States LakeView Clinical Research Guntersville Alabama
United States Advantage Foot Care of Houston Houston Texas
United States Biolife Genetics Research Houston Texas
United States Clemente Clinical Research Los Angeles California
United States VA Northern California Health Care System Mather California
United States Northwell Health Comprehensive Wound Healing Center New Hyde Park New York
United States Gateway Clinical Trials, LLC O'Fallon Illinois
United States CureCentric Palmdale California
United States UPMC Center for Innovation in Restorative Medicine Pittsburgh Pennsylvania
United States Reno Orthopedic Clinic Reno Nevada
United States Bio-X-Cell Research San Antonio Texas
United States Banner University Medical Center Tucson Tucson Arizona
United States Curalta Foot and Ankle Westwood New Jersey
United States PIH Health Whittier California

Sponsors (1)

Lead Sponsor Collaborator
Tissue Tech Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete wound healing Time from baseline to initial observation of healing, where healing has been confirmed at two consecutive visits each two weeks apart. over 25 weeks
Secondary Wound durability Proportion of wounds that re-ulcerate by Week 26
Secondary Limb preservation proportion of minor and major amputations following the initial procedure by Week 26
Secondary Patient-reported mobility compare total score on PROMIS Health Organization Neuro-QoL 'lower extremity function'; scale from 1-5; higher scores indicate better self-reported health Baseline to End of Study (approximately 26 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Recruiting NCT05613985 - PHOTOFINISH: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers N/A
Recruiting NCT03964571 - Human and Bacterial Protease Activity as Prognostic Tool of Foot Infections in Diabetic Patients N/A
Completed NCT03230175 - Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01) Phase 2
Completed NCT05616351 - Antibiotic Therapy in Infections of the Diabetic Foot Syndrome
Recruiting NCT05948592 - Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection Phase 2
Recruiting NCT04714411 - Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis
Completed NCT05243810 - EPC Silver Wound Gel (EPC-123) Feasibility Study in the Management of Mildly Infected Diabetic Foot Ulcers N/A
Recruiting NCT05610865 - Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers Phase 1
Recruiting NCT05369052 - Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI) Phase 3
Completed NCT02723539 - A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI Phase 1
Completed NCT04440839 - Implementation of Telemedicine for Patient With Lower Extremity Wounds N/A
Withdrawn NCT04289948 - Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes Phase 1/Phase 2
Completed NCT03495349 - Effectiveness and Safety of Antibiotherapy in Diabetic Patients Treated for a Diabetic Foot Infection.
Completed NCT05564728 - Diabetes Footcare Companion App for Patients and Carers
Withdrawn NCT03354806 - Peripheral Analgesia in Painful Diabetic Neuropathy N/A
Completed NCT01590758 - Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers Phase 3
Completed NCT01594762 - Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers Phase 3
Active, not recruiting NCT05174806 - Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients Phase 2
Recruiting NCT04141787 - Ceftriaxone as Home IV for Staph Infections Phase 4